Business Context and Reporting Period
This Form 8-K was filed by LIFECORE BIOMEDICAL, INC. on January 10, 2024. The report addresses a notification received from The Nasdaq Stock Market LLC regarding the Company's failure to satisfy continued listing requirements due to delays in filing periodic reports with the SEC.
Key Financial Metrics
This filing is a current report regarding regulatory compliance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Status
- Delisting Notice: The Company received a notice from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to delayed filings.
- Missing Filings: The Company has not filed its Annual Report on Form 10-K for the period ended May 28, 2023, its Q1 Form 10-Q for the quarter ended August 27, 2023, or its Q2 Form 10-Q for the quarter ended November 29, 2023.
- Trading Status: The notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market.
- Compliance Plan: A previously approved compliance plan granted the Company an exception period until February 12, 2024, to file the overdue 10-K and Q1 10-Q. The Company plans to submit an updated plan by January 25, 2024, to address the Q2 10-Q.
Outlook, Risks, and Management Commentary
Management states it is working diligently to complete the required filings and intends to file them as promptly as possible to regain compliance. However, the Company explicitly states there can be no assurances that it will complete the filings or regain compliance prior to the expiration of the exception period on February 12, 2024.
Key Risks Identified:
- Failure to respond timely to Nasdaq inquiries.
- Inability to regain compliance with Listing Rule 5250(c)(1) before the exception period expires.
- Delays in becoming current with SEC reports.
Investor Verification Checklist
- Verify the status of the Company's compliance plan update expected by January 25, 2024.
- Monitor whether the overdue Form 10-K and Form 10-Q reports are filed before the February 12, 2024 deadline.
- Check for any subsequent Nasdaq communications regarding potential delisting if the exception period expires without compliance.
- Review the attached press release (Exhibit 99.1) for additional details on the regulatory situation.